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1. Introduction 
Head and neck cancers are different types of tumours  found  in the upper aero-digestive 
tract. The vast majority of them (more than 90%) are squamous cell carcinomas (HNSCC) 
that originate in the epithelium lining of the oral cavity, pharynx and larynx. There is a 
higher incidence rate in males compared to females (Ragin et al, 2007). The median age of 
patients with HNSCC is about 60 years (Ragin et al, 2007). Young patients make up 1-8% 
(Llewellyn et al, 2004). HNSCC comprise 5.5% of all incidence cancers (Mitra et al, 2007) and 
is the sixth leading cancer worldwide with approximately 600,000 cases reported annually 
(Leemans et al, 2011). Local recurrence affects about 60% of patients and metastases develop 
in 15-20% of cases (Choi & Chen, 2005). About 40-50% of patients with HNSCC survive for 5 
years (Leemans et al, 2011). About one third of patients are diagnosed with early-stage 
disease, whereas the majority are diagnosed with advanced stage cancer with lymph node 
metastases. Early stage tumours are treated by surgery or radiotherapy ensuing more 
favourable prognosis. Surgery is the main source of treating advanced tumors combined 
with post-operative chemo- and radio-therapy. Over the past two decades, the quality of life 
of patients with HNSCC has increased due to the ample use of more advanced surgical and 
radiotheraupeutic techniques, as well as organ preservation protocols. Despite these 
improvements, survival has not markedly improved because patients still frequently 
develop local-regional recurrences, distant metastases and second primary tumors. The 
TNM staging system, that is most often used to classify patients with HNSCC, is based on 
the clinical, radiological and pathological examination of tumor specimens. This system 
does not adequately address the molecular heterogeneity of HNSCC and the ability of 
staging to predict prognosis in HNSCC is limited because patients with tumours with the 
same clinicopathologic stage do not have the same disease progression, response to therapy, 
rate of disease recurrence and survival (Leemans et al, 2011; Choi & Chen, 2005). Ongoing 
molecular studies show that these HNSCC may not be considered as homogenous as 
previously supposed (Pai & Westra, 2009). Recognition of distinct molecular and genetic 
profiles could permit finer resolution of HNSCC into distinct subtypes that differ with 
regard to risk factors, pathogenesis and clinical behavior. A more detailed molecular 
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characterization ultimately is likely to improve the development of new therapeutic 
strategies, potentially relevant to diagnosis and prognosis of this poorly defined subset of 
head and neck cancers. 
2. Risk factors 
The main risk factor for HNSCC is tobacco smoking. This risk is strongly correlated with the 
time and rate who person smokes. In fact, when a person stops smoking it reduces the risk 
of developing cancer (Schlecht et al, 1999). Besides environmental exposure to tobacco 
smoke, passive smoking appears to increase the risk of developing HNSCC, even for 
individuals who have never actively smoked (Zhang et al, 2000). This increased risk is 
mostly attributable to the genotoxic effects of carcinogens in tobacco smoke, including 
nitrosamines and polycyclic hydrocarbons. Tobacco smoking has showed to have site 
specific differences in the anatomical sub-regions, with an increase in sensitivity from the 
oral cavity down to the larynx (Werbrouck et al, 2008). Tobacco has also proven to be a 
significant prognostic marker (Ragin et al, 2007; Leemans et al, 2011). Identifying the 
molecular targets of cigarette smoking in order to discern a specific profile of tobacco-
induced mutations is still currently being studied. TP53 mutations and overexpression in 
HNSCC, for example, occur more frequently in patients who smoke than in patients who do 
not smoke (Field et al, 1991; Ronchetti et al, 2004). Much attention has been focused on 
genetic polymorphisms in those enzymes that activate pro-carcinogens and detoxify 
carcinogens; however no clear-cut association has been established yet. Heavy use of alcohol 
has also been recognized as an independent risk factor for HNSCC, particularly for cancer of 
the hypopharynx (Sturgis et al, 2004). However, alcohol consumption is mainly relevant for 
its ability in magnifying its effects with tobacco smoke in a synergistic manner (Talamini et 
al, 2002). Its ability in enhancing the effects of smoking most likely resides in its nature as a 
chemical solvent, increasing and prolonging mucosal exposure to the carcinogens present in 
tobacco (Pai & Westra, 2009). In addition, although alcohol itself is not a direct carcinogen, 
its metabolites and acetaldehyde form DNA adducts that interfere with DNA synthesis and 
repair. Polymorphisms in the enzymes that metabolize alcohol to acetaldehyde have not 
been conclusively associated with modifying cancer risk. A subgroup of HNSCC, 
particularly those of the oropharynx and oral cavity, is also caused by high risk infection 
types of human papillomavirus (especially HPV-16 and 18) (Chung & Gillison, 2009; 
Leemans et al, 2011). HPV has been established as a causative agent in about 70% of oral 
cavity and oropharyngeal cancers. The vast majority of HPV-positive HNSCC localizes to 
the tonsillar crypts of the lingual and palate tonsils. Its structural features render them 
particularly vulnerable to HPV attack (Pai & Westra, 2009). The traditional risk factors, 
tobacco and alcohol use, do not appear to play a contributing role in HPV-related cancers 
(D’Souza et al, 2007). Certain sexual practices that facilitate repeated viral exposure are 
strongly associated with HPV oral infection (Smith et al, 2004). Although the risk factors for 
HPV viral infection are well recognized, those associated with subsequent HPV-induced 
tumorigenesis are now only coming into focus. However, it is known that HPV-positive and 
negative tumours represent different clinical pathological and molecular entities (Table 1) 
and that HPV-related tumours, which constitute about 20% of all HNSCC subtypes, are 
associated with a more favorable outcome (Chung & Gillison, 2009, Leemans et al, 2011). 
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 HPV positive HPV negative 
Risk factors High-risk sexual behavior  Smoking and alcohol use 
Predilection site 
Oropharynx and oral cavity especially 
lingual and palatine tonsil  
None 
Main molecular 
genetic 
alterations 
Infrequent p53 mutations, degradation of 
p53-Rb pathway by HPV E6/E7 protein 
High frequency of p53 
mutations, 17p and 9p 
loh, loss of p16 expression  
Prognosis Better Worse 
Table 1. Main characteristics of HPV+ and HPV- HNSCC 
3. Genetic alterations 
It is well known that HNSCC is the result of a multistep process characterized by the 
accumulation of genetic and epigenetic alterations (Ha et al, 2009). The genetic alterations 
associated with HNSCC are numerous and include a variety of different pathways (Table 2). 
The accumulation and selection of these aberrant pathways may sometimes be due to 
random chance, but more commonly, they are attributable to a lifetime of environmental 
exposure to tobacco, alcohol and HPV infection. Therefore, the chance of DNA damage is 
high and often there is an accumulation of genetic events that lead to the development of 
HNSCC (Ha et al, 2009). Genetic alterations, including copy number variations (CNV), gains 
or losses of heterozigosity (LOH) may cause the inactivation of tumor suppressor genes and 
the activation of oncogenes, which in turn lead to uncontrolled cell growth and metastasis 
(Chen & Chen, 2009). In order to identify the genetic alterations, such as chromosomal 
deletions and/or amplifications, the presence of Single Nucleotide Polymorphisms SNPs or 
mutations in oncogenes/tumour suppressor genes or other genes, different techniques can 
be adopted from various low throughput and high throughput methods (Ha et la, 2009). The 
low throughput resolution methods are brought about by a study of CNV/LOH using 
polymerase chain reaction (PCR) -related methods and fluorescence in situ hybridization 
(FISH). The high throughput resolution methods are the array-related methods, such as 
Comparative Genomic Hybridization (CGH) array, to identify genome wide CNV/LOH 
events. The arrays have the ability to finely map regions of chromosomal gain or loss, much 
more accurately than the conventional molecular techniques. Regions of chromosomal loss 
commonly reported are at 1p, 3p, 4p, 5q, 8p, 10p, 11q, 13q and 18q, while those that are 
frequently gained are at 1q, 3q, 5p, 7q, 8q, 9q, 11q, 12p, 14q  and 15q (Ha et al,  2009; 
Wreesmann & Singh, 2005). Most possibly, the presence of CNV/LOH has the potential to 
 
Locus or gene Frequency in HNSCC 
LOH 3p 60-70% 
LOH 9p 70-80% 
LOH 11q 30% 
LOH 13q 30% 
LOH 17p 50-70% 
p16 inactivation  80% 
Cyclin D1 amplification 30% 
FHIT, RASSF1A inactivation  50-80% 
TP53 mutations 60-80% 
Table 2. Frequent molecular abnormalities in HNSCC (Perez-Ordonez et al, 2006)  
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serve as a prognostic indicator, alone or in combination with other markers, to identify 
HNSCC patients at high risk of recurrence and death (Chen & Chen, 2008). 
3.1 The molecular biology of field cancerization of HNSCC 
In 1953, the term “field cancerization” was introduced to explain two phenomena: (1) the 
high tendency to develop local recurrences after treatment of HNSCC and, (2) the high 
likelihood that multiple independent tumours would develop in the head neck mucosa (Ha 
& Califano, 2003). According to this concept, molecular genetic approaches have recently 
shown that when a primary HNSCC is compared with a second tumour elsewhere in the 
respiratory tract, the paired tumours often harbor some identical patterns of genetic 
alterations (Pai & Westra, 2009). In all probability, a critical genetic alteration may be a 
single cell providing a growth advantage over its neighboring cells. These cells can migrate 
to populate continuous tracts of mucosa, accumulate other alterations, acquire additional 
growth advantage and ultimately transform into aggressive subclones separated by time 
and space (Califano et al, 2000). It is important to note that, the epithelium of the upper 
respiratory tract may be populated by these genetically damaged clones and may lack 
hystopathological evidence of dysplasia. Thus, the presence of morphologically intact but 
genetically damaged cells may perhaps explain the mechanism  underlying cancerization as 
well as certain distress patterns of tumour behavior, such as local recurrences following 
seemingly to complete surgical resection. A current model of HNSCC progression associates 
the loss of chromosomal arms 3p, 9p and 17p with conversion from normal to dysplastic 
epithelium. Subsequent loss of 11q, 13q and 14q is associated with progression to carcinoma 
in situ, with the loss of 6p, 8p, 8q and 4q seen in more advanced stages with invasive 
property (Califano et al, 1996; Choi & Chen, 2005; Perez-Ordonez et al, 2006) (fig.1). 
 
Fig. 1. HNSCC carcinogenesis model, modified from Califano et al. (1996) 
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3.2 Molecular genetics of premalignant oral lesions 
HNSCC develops from normal aereodigestive mucosa progressing through a series of 
histological identifiable pre-malignant stages. In particular, oral squamous cell carcinomas 
(OSCC) may be preceded by the appearance of lesions, which have the potential to develop 
into cancer in the oral cavity. The development of OSCC is generally expected upon the 
development of multiple, clonal, genetic alterations, which lend a clonal population of cells 
a growth advantage over others. The distinction between benign and potentially malignant 
oral lesions is currently based upon the histological examination of biopsy specimens. In the 
absence of a carcinoma or dysplasia, the ability to quantify the risk associated with 
malignant transformation is limited. It is for this reason that a molecular and genetic 
characterization of premalignant lesions may be very important in predicting their 
malignant potential. There are several histologically distinct lesions of the oral cavity that 
have malignant potential. These are leukoplakia, erythroplakia, lichen planus and 
submucous fibrosis, together with a spectrum of chromosomal, genetic and molecular 
alterations. The degree of similarity to OSCC found in premalignant lesions is dependent 
upon the presence of atypia. However, individual lesions may present molecular genetic 
alterations similar to OSCC, even in the absence of histologically defied dysplasia  
(Mithani et al, 2007). 
Leukoplakia, defined as a predominantly white lesion of oral mucosa that cannot be 
characterized by any other definable lesion, is the most commonly diagnosed premalignant 
lesions in the oral cavity (Mithani et al, 2007). It is also strongly associated with the 
development of OSCC. Patients with oral leokoplakia have up to 36% incidence of 
subsequent OSCC development, only if the lesion demonstrates dysplastic features. In the 
absence of dysplasia, these lesions still possess a 15% incidence of cancer development 
(Mithani et al, 2007). In particular, increased LOH was correlated to the histopathological 
progression in the upper aereodigestive tract (Califano et al, 1996). 50% of leukoplastic 
lesions contain allelic loss of either the 3p or 9p chromosome arms, which are associated 
with higher risk of malignant transformation. This risk increases further in the presence of 
additional LOH at the 4q, 8p, 11q, 13q and 17p loci (Rosin et al, 2000). Insertions or deletions 
of base pairs at microsatellites, termed microsatellite instability (MSI), are another 
cytogenetic feature shared between premalignant lesions and OSCC. The MSI is present in 
55% of leukoplakia and there is a trend towards increasing MSI prevalence associated with 
histological progression of premalignant lesions (Mithani et al, 2007). In addition, many 
studies have demonstrated a trend in increasing polysomy at several loci, such as 
chromosomes 7 and 17, in the progression of the aeredigestive tract. For example, lesions 
with a >3% proportion of cells with trisomy 9 have a significantly higher likelihood of 
progression in cancer (Lee et al, 2000; Mithani et al, 2007). It is also demonstrated that 
telomerase activity is correlated with the degree of atypia and dysplastic changes (Mithani 
et al, 2007). Finally, mitochondrial genomic mutations, which occur in response to oxidative 
damage and stress, may have a role in the development of cancer, including HNSCC 
(Sanchez-Cespedes et al, 2001). The mechanism by which these mutations contribute to 
carcinogenesis has not yet been demonstrated. It has been postulated to occur because of 
mitochondrial dysfunction in apoptosis or through reactive oxygen species generation 
(Gottlieb & Tomlinson, 2005). Epigenetic changes are also important. An aberrant 
methylation of CpG-rich regions of the promoters prevents gene transcription by altering 
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the structure of histone complex. Promoter hypermetilation is a mechanism by which 
tumour suppressor genes are transcriptionally inactivated (Ha & Califano, 2006). There are 
few studies on the aberrant methylation occurring in leukoplakia, where the 
hypermetylation of RAR-b2 (Youssef et al, 2004), p16 and MGMT (Lopez et al, 2003) has 
been shown. These genes are metylated also in OSCC.  
3.3 Association between genetic alterations and poor outcome of HNSCC patients 
Various studies indicate that many of the LOH events in certain chromosomal regions are 
associated with shorter survival of HNSCC patients. The most commonly reported CNV 
and LOH associated with survival pertain to chromosomal regions 11q, 3q, 7p and 22q (for 
CNV) and in 3p, 8p and 9p, 13q (for LOH) (Chen & Chen, 2008). For example, many studies 
identified a consistent amplification in the head and neck tumours at region 11q13. Possibly 
the amplification of this region plays an important role in HNSCC survival, given the many 
known oncogenes, such as bcl-1, Int-2, hst-1, EMS1, CCND1 and PRAD1, in turn are 
correlated with clinical outcomes, that reside in this region (Chen & Chen, 2008). As far as 
recurrence is concerned, the most commonly reported CNV/LOH events associated with 
recurrence involved CNV at 11q and LOH at 9p and 17p (Chen & Chen, 2008). Only few 
papers focus on the combination of histopathological and clinical characteristics, such as 
tumour size, lymph node status and metastasis (TNM) staging or treatment condition and 
the data results from CNV and/or LOH to predict survival. For example, the association 
between 3p LOH and poor outcome in HNSCC patients with early stage I and II tumours 
was shown (Partridge et al, 1996). Other research has also shown that patients who received 
radiotherapy, 6q LOH was associated with reduced survival (Jamieson et al, 2003). 
3.3.1 Genetic polymorphism and their association with outcomes in HNSCC 
Single nucleotides polymorphisms (SNPs) are a DNA sequence variation occurring when a 
single nucleotide in the genome differs between members of a biological species or paired 
chromosomes in an individual.  This variation in DNA sequences may not lead to an amino 
acid alteration and do not seem to have any adverse effects in “normal” individuals.  It is 
possible to perform the analysis of SNPs using PCR-related methods, such as direct 
sequencing, or using SNP arrays.  These SNPs may be markers for disease predisposition, or 
may be used to genetically identify patients, as they tend to cluster with ethnic background. 
Recent results from case-control studies of several phenotypic and genotypic assays support 
the hypothesis that genetic susceptibility or predisposition plays an important role in 
HNSCC aetiology (Negri et al, 2009; Garavello et al, 2008; Ingelman-Sundberg, 2001). It has 
been hypothesized that susceptibility to disease development is based on inherited 
differences in the efficiency of carcinogen metabolism, DNA repair and cell cycle control, or 
a combination of these. SNPs located in DNA repair genes can modulate DNA repair 
capacity and, consequently, alter cancer risk. In particular, it was shown that, among all 
DNA repair pathways, the sequence variations in the base excision repair (BER) pathway 
may contribute to HNSCC susceptibility. For example, a significantly decreased risk of 
HNSCC was associated with the adenosine diphosphate ribosyl transferase  (ADPRT) 
762Ala/Ala genotype and the combined ADPRT Val/Ala and ADPRT Ala/Ala genotypes, 
compared with the ADPRT Val/Val genotype (Li et al, 2007). An association between the 
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presence of cytocrome P450 (CYP) and GSTs allelic variants, which are families of enzymes 
involved in the metabolism of many environmental agents, including tobacco and alcohol, 
and increased risk of HNSCC was also demonstrated. In particular, it was observed that the 
CYP1A2*1D variant allele confers an increased risk of HNSCC, while the CYP1A2*1C 
polymorphism was associated with tumour recurrence (Olivieri et al, 2009). Finally, 
CYP2E1*5B and GSTM1 null alleles were associated with advanced clinical stages (Olivieri, 
2009). In conclusion, it is clear that genetic polymorphisms may act as predictors of risk and 
are also associated with tumour recurrence, since they are important for determining the 
parameters associated with tumour progression and poor outcomes in HNSCC. For these 
reasons, the identification of individuals presenting polymorphic variations would have an 
impact on primary prevention and early detection strategies. 
3.3.2 Genetic polymorphism and their association to tobacco and alcohol use 
Smoking and the consumption of alcohol are the main risk factors for head/neck cancer. 
Although the chance of developing HNSCC increases with the level of tobacco smoking and 
alcohol use, it is obvious that not every (heavy) smoker and/or drinker develops HNSCC. 
The risk for an individual to develop HNSCC after exposure to tobacco carcinogens, may 
therefore also depend on sequence variation in the genes (genetic polymorphisms) coding 
for the enzymes involved in the detoxification of tobacco smoke carcinogens, such as 
microsomal epoxide hydrolase (mHE), gluthatione-S-transferase (GSTs) and uridine 5’-
diphosphate (UDP)-glucuronosyltransferase (UGTs). Genetic polymorphisms in these genes 
may alter their activity and may thus modulate the risk of HNSCC. For example, the 
presence of null polymorphism in GSTM1 or GSTT1 was associated with an increased risk 
for HNSCC in smokers (Lacko et al, 2009). For the UGTs, both the variants UGT1A7 and 
UGT1A10 were associated with an altered risk of developing cancer (Lacko et al, 2009). 
Tobacco smoke is associated with the increased formation of DNA lesions, which can be 
repaired also by BER pathway. Therefore, also an individual variation in BER, is one of the 
host factors that may influence tobacco smoking-related HNSCC risk. The Rad1 c.3429 G>C 
polymorphism has a more evident association with cancer risk in the group of heavy 
smokers (Werbrouck et al, 2008). Detoxification of tobacco smoke carcinogens, together with 
DNA repair and apoptotic pathways, is probably the most important rescue pathways in 
preventing the development of tobacco-induced HNSCC. In fact, the activity of such 
enzymes may differ between individuals and this is one of the possible explanations for the 
differences in inter-individual susceptibility for the development of HNSCC.  
3.4 Epigenetic alterations 
HNSCC is a result of multiple genetic and epigenetic alterations. Epigenetic is defined as the 
stable inheritance of information based on gene expression levels without changing the 
underlying genetic code (Esteller et al, 2002). These heritable modifications of the DNA 
molecule itself occur through several pathways including alterations in DNA methylation 
and histone modifications mediated by: DNA methyltransferases (DNMT), methyl-CpG-
binding domain proteins, histoneacethyltranferases (HAT), histone deacetylases (HDAC), 
histone methyltransferases (HMT) and histone demethylases (Glazer et al, 2009). Epigenetic 
changes have been associated with cancer specific expression differences in human 
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malignancies, including HNSCC (Herman et al, 2003). These alterations are known to occur 
early in tumoriginesis and are associated with distinctive cancer types. The main epigenetic 
modification found in humans is the methylation of the 5’ carbon of the cytosine ring within 
cytosine-guanine dinucleotides (CpGs) by the enzyme class methyltransferases. CpG 
methylation occurs in patterns both species and tissue specific, serving to block transcription 
and recruit histone and modifying tightly packed heterochromatin and gene silencing. 
DNMTs are responsible for maintaining the methylation status of a gene in the cell’s 
progeny. In addition, histone modification has also been shown to play an active role in 
regulating gene expression. Histone modifications and DNA methylations play a significant 
role in the organization of nuclear structure, ultimately influencing gene expression. The 
epigenetic inactivation of tumor suppressor genes is an important event in HNSCC 
(Steinmann et al, 2009; Glazer et al, 2009). In recent years, new assays, such as sodium 
bisolfite treatment of DNA, which converts the non-methylated cytosines to uracyl, and 
methylation sensitive quantitative PCR, have further advanced the ability to evaluate the 
methylation status of tissue samples. In HNSCC, the promoter hypermethylation of p16 is a 
frequent event (Reed et al, 1996; Glazer et al, 2009; Steinmann et al, 2009). Studies on 
promoter methylation have uncovered many other genes in HNSCC, such as DIM-6, ATM, 
p15, TIMP-3, MGMT, RARB-2, DAP-K, E-cadherin, Cyclin A1, RASSF1A, CDKN2A, CDH1 
and DCC (Steinmann et al, 2009). These genes are involved in pathways that control cell 
cycle progression, apoptosis, cell-cell adhesion, DNA repair and tumour invasion. A trend 
toward an increased methylation of these genes in more advanced tumour stages and less 
differentiated HNSCC was observed. In particular, p16 methylation was significantly high 
in poorly differentiated HNSCC and RASSF5 methylation occurred preferentially in 
advanced tumour stages, while methylation of RASSF4 was higher in patients with 
recurrence (Steinmann et al, 2009). A relationship between methylation profiling, tumour 
stage and age of patients was also shown (Marsit et al, 2009). A borderline significant 
association between tumour site and methylation pattern was also observed (Marsit et al, 
2009). These data reveal that patterns of epigenetic alteration may hold a relevant role in 
identifying the process through which carcinogens act epigenetically to drive 
tumourigenesis as well as in providing useful tools with diagnostic value. 
3.4.1 Epigenetic alterations and correlation with aetiologic agents and clinical 
parameters 
DNA methylation-associated epigenetic silencing of tumor suppressor genes is an aberrant 
marker of cancer with considerable specificity. An association among HPV, tobacco smoking 
and alcohol exposure and methylation of specific genes has been identified. In particular, 
using a whole genome profiling approach, not only was there a correlation between 
methylation and tobacco and alcohol use, but also in considering smoking intensity (packs 
per day) and lifetime average drinks per week (Marsit et al, 2009). Tumour HPV16 DNA 
status also demonstrated to have an association with methylation, showing that HPV+ and 
HPV- HNSCC patients do not only have a different pattern of methylation, but have a more 
pronounced hypomethylation in HPV-negative tumours than in HPV-positive tumours 
(Richards et al, 2009). In addition, genomic instability, as measured by genome-wide loss of 
heterozogosity (LOH) and single nucleotide polymorphism (SNP) analysis, is greater in 
HNSCC samples with more pronounced hypomethylation. For example, epigenetic 
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inactivation of the SFRP genes is associated with drinking, smoking and HPV. Promoter 
methylation of SFRP1 occurred more often in both heavy and light drinkers compared to 
non drinkers. SFRP4 promoter methylation, on the other hand, occurred at a higher 
prevalence in never smokers and former smokers than in current smokers, and also was 
independently associated with HPV16 viral DNA (Marsit et al, 2006).   
4. Potential molecular prognosis markers in HNSCC 
HNSCC has long been a challenge in regards to treatment because of the high rate of 
recurrences and advanced diseases at the time of diagnosis. Molecular identification of 
tissue biomarkers in diagnostic biopsy specimens may not only identify patients at risk for 
developing HNSCC but also select patients that may benefit from more aggressive 
treatment methods. In addition, they may potentially offer new methods for early diagnosis, 
monitoring and treatment alternatives for HNSCC patients. Some emerging molecular 
markers include TP53, epidermal growth factor receptor (EGFR), cyclin D1, transforming 
growth factor alpha (TGF-alfa), p16INK4A, cyclooxigenase-2 (Cox-2), vascular endothelial 
growth factor (VEGF) and matrix metallo proteinases (MMPs) (Table 3).  
 
Molecule 
name 
Genomic 
localization 
Function From literature References  
TP53 17p13 A tumor-
suppressor 
regulating cell 
cycle 
progression, 
apoptosis and 
cell survival 
 60-80% of HNSCC 
shows TP53 somatic 
mutations causing mostly 
p53 protein 
overexpression. 
 Predictive and 
prognostic value for 
survival, recurrence, 
treatments response and 
lymph node status 
- Bradford et al, 2003 
- Cabanillas et al, 2007 
- Cabelguenne et al, 2000 
- Gasco and Crook, 2003 
- Graveland et al, 2011 
- Lassaletta et al, 1999 
- Leemans et al, 2011 
- Nees et al,1993 
- Nogueria et al, 1998 
- Nylander et al, 2000 
- Perrone et al, 2010 
- Poeta et al, 2007 
- Quon et al, 2001 
- Temam et al, 2000 
- Thomas et al, 2005 
p16INK4A 
(CDKN2A) 
 
9p21 A tumor-
suppressor 
regulating 
senescence and 
cell-cycle 
progression by 
acting as an 
inhibitor of 
cyclin dependent 
kinase 4 and 6-
cyclin D 
complexes 
 50-80% of HNSCC 
shows loss of p16 
expression, mostly by 
promoter 
hypermethylation or 
homozygous deletion. 
 Prognostic value 
for survival and 
development of distant 
metastases 
 High p16 
expression in combination 
with persistent HPV16-18 
infection predicts a better 
prognosis 
- Ambrosch et al, 2001 
- Bazan et al, 2002 
- Broek et al, 2009 
- Thomas et al, 2005 
- Namazie et al, 2002 
- Thomas et al, 2005 
- Yuen et al, 2002 
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Molecule 
name 
Genomic 
localization 
Function From literature References  
PTEN 10q23 A tumor 
suppressor gene 
regulating 
signaling 
pathways 
controlling cell 
proliferation and 
apoptosis 
 30% of HNSCC 
shows loss of PTEN 
 Potential 
prognostic value in 
relation to poor outcome. 
 Association 
between PTEN 
overexpression  and 
increase of radioresistance 
- Mriouah et al, 2010 
- Pai and Westra, 2009 
- Pattje et al, 2010 
- Pedrero et al, 2005 
 
Cyclin D1 11q13 Proto-oncogene 
regulating cell 
cycle progression 
 17-79% of HNSCC 
shows amplification and 
overexpression of cyclin 
D1 
 Prognostic value in 
relation to more advanced, 
aggressive disease, lymph 
node metastasis and 
reduced survival 
- Akervall et al, 1997 
- Capaccio et al, 2000 
- Holley et al, 2005 
- Kumar et al, 2003 
- Leemans et al, 2011 
- Marsit et al, 2008 
- Michalides et al, 1997 
- Namazie et el, 2002 
- Nimeus et al, 2004 
- Okami et al, 1999 
- Pyeon et al, 2007 
- Thomas et al, 2005 
- Volavsek et al, 2003 
EGFR 7p11 Trans membrane 
TK acting as a 
central 
transducer in 
multiple 
pathways that 
mediate cell 
cycle 
progression, 
angiogenesis, 
inhibition of 
apoptosis, tumor 
invasion and 
metastasis 
 34-90% of HNSCC 
shows overexpression of 
EGFR 
 Prognostic value in 
relation to disease free 
survival and overall 
survival; association with 
a shorter overall survival 
and poor outcomes. 
 From 2006 use of 
therapy based on EGFR 
inhibitors 
- Carracedo et al, 2008 
- Chang et Califano, 2008 
- Hama et al, 2009 
- Kalyankrishna and 
Grandis, 2006 
- Quon et al, 2001 
- Smilek et al, 2006 
- Uribe & Gonzalez, 2011 
VEGFs  Ligands of trans 
membrane TK 
promoting cell 
proliferation, 
migration and 
survival of 
endothelial cells 
during tumor 
growth 
 90% of HNSCC 
shows overexpression of 
VEGFs (especially A and C 
forms), 
 They are important 
pro-angiogenic factors, 
which promote 
neovascularization in 
cancer.  
 They are associated 
with tumor growth, 
metastasis, treatment 
failure and shorter overall 
survival 
- Kyzas et al, 2004 
- Kyzas et al, 2005 
- Lentsch et al, 2006 
- Mineta et al, 2000 
- Moryama et al, 1997 
- Neuchrist et al, 2001 
- Neuchrist et al, 2003 
- Petruzzelli et al, 1997 
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Molecule 
name 
Genomic 
localization 
Function From literature References  
Cox2 1q25.2–25.3 Catalytic enzyme 
decreasing 
apoptosis, 
increasing 
inflammation 
and important 
for tumor 
progression 
 Presence of Cox 2 
up regulation in tumor 
(150 folds) and adjacent 
tissues (50 folds) 
compared to nomal 
epithelium. 
 It seem to be an 
early event in HNSCC 
carcinogenesis 
 Prognostic value 
for survival;  Cox 2 
overexpression in 
combination with PEG2 is 
associated with a shorter 
overall survival 
 Prognostic marker 
in premalignant lesions. 
 Low levels of Cox 
2 are associated with 
poorer overall survival in 
larynx cancer 
 Independent 
predictor of disease-free 
survival. 
 Ongoing 
preclinical studies with 
therapy based on Cox-2 
inhibitors in combination 
with EGFR inhibitors 
- Gallo et al, 2002 
- Itoh et al, 2003 
- Ranelletti et al, 2001 
- Sudbo et al, 2003 
- Thomas et al, 2005 
TGF alfa 2p13 Growth factor 
inducing 
epithelial 
development 
and primary 
ligand of the 
EGFR 
 Association 
between TGFA 
overexpression and poor 
outcome and response to 
anti-EGFR therapy 
- Logullo et al, 2003 
- Quon et al, 2001 
- White et al, 2010 
MMPs  Family of Zn-
dependent 
proteolytic 
enzymes that 
degrade the 
basement 
membrane and 
other 
components of 
the extracellular 
matrix 
 Overexpression in 
HNSCC of various MMPs,  
including MMP2, MMP8, 
MMP13 
 Association with 
poor outcome, cisplatin 
resistance, lymph node 
metastasis and early 
recurrence. 
 Evidences about 
association between the 
EGFR signaling and 
MMPs activation 
- Kusukawa et al, 1996 
- O-Charoenrat et al, 2000 
- Patel et al, 2005 
- Sinpitaksakul et al, 2008 
- Thomas et al, 2005 
Table 3. Biomarkers in head and neck cancers 
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4.1 TP53 
TP53 is a tumour suppressor gene located on chromosome 17p13 and consists of 11 exons 
that encode protein p53, and functions in carcinogenesis by initiating G1 arrest in response 
to certain DNA damage and apoptosis. Studies suggest that after mutation in one TP53 
allele, the remaining wild type (w.t.) allele is often deleted and therefore the mutant 
phenotype is expressed (Yin et al, 1993; Kiuru et al, 1997). The prevalence of TP53 mutations 
is 20–70% in HNSCC (Blons et al, 2003). The reported frequency of the mutations varies 
among different studies. This is related, at least in part, to techniques used for detecting 
mutations, the regions of the TP53 gene analyzed, and the anatomic site of the analyzed 
sample tumours. Exons 5 to 8 (encoding the “core” domain) of TP53 are the most analyzed 
because they represent the major site of TP53 mutations. However, other studies report that 
a considerable amount of HNSCC carries TP53 mutations outside the core domain of p53 
(Balz et al, 2003; Saunders et al, 1999).  
4.1.1 Tobacco and TP53 
An explanation for the heterogeneity of TP53 mutation frequency could be the different 
levels of exposure to risk factors in the population studied. In fact, the frequency of TP53 
mutation in patients with invasive HNSCC was related to the level of exposure to cigarette 
smoke and alcohol (Blons et al, 2003; Ronchetti et al, 2004; Hussain et al, 1999). The 
frequency of somatic TP53 mutation in smoking HNSCC patients was at least double 
compared to non-smoking HNSCC patients (Field et al, 1991). DNA can be damaged by 
numerous tobacco carcinogens and environmental chemicals that can be activated or 
degraded by specific enzymes termed xenobiotic-matabolizing enzymes (XMEs). The 
existence of XMEs variants may explain individual susceptibility to TP53 mutations. An 
XME genotype that results in increased DNA damage as a consequence of altered 
carcinogen metabolism could increase the incidence of TP53 mutations (Blons et al, 2003). 
For example, a strong association between TP53 mutation and CYP1B1 genotypes was 
found in smokers (Ko et al, 2001; Thier et al, 2002). Finally, an increased sensitivity to 
mutagens as a result of low DNA repair capacity increases the frequency or modify the 
pattern of TP53 mutations (Casse et al, 2003; Wong et al, 2002). As expected from 
experimental tobacco carcinogenesis, the most prevalent mutations in HNSCC are G:C>A:T 
transitions and G:C>T:A tranversions. It is also interesting to note that frameshift mutations, 
which are more frequent in patients exposed to both alcohol and tobacco, occur more 
frequently in HNSCC than in other tobacco-independent cancer types (Blons et al, 2003). 
4.1.2 Is TP53 mutation an early or a late event? 
The expression of the p53 protein has been detected also in oral premalignant lesions (such 
as leukoplakia), where it may indicate an impending malignancy. Specifically, suprabasal 
expression has been highly predictive of malignant development (Cruz et al, 1998). In 
addition, when surgical margins of primary HNSCC are examined for mutational changes, 
there is an increased risk of local recurrence when positive margins demonstrating clonal 
alterations in TP53 are observed (Graveland et al, 2011). However, there have been 
conflicting conclusions concerning the stage at which TP53 mutations occur during HNSCC 
carcinogenesis. Early studies performed by immunocytochemistry suggested that TP53 
alterations are an early event in the carcinogenesis of HNSCC. In contrast, subsequent 
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studies have found that TP53 mutations represent a late event and are associated with an 
invasive phenotype (Shahnavaz et al, 2000; Shin et al, 2000). Whether this is due to different 
methods in the evaluation of TP53 mutations or whether they define new subgroups in the 
HNSCC is still an open question. As described, TP53 mutations are frequently detected by 
immunohistochemical analysis. This simple analysis is based on the finding that mutant p53 
protein, adopting an altered conformation, becomes very stable, facilitating its detection and 
allowing its use as a marker for gene mutation. However, not all types of mutations are 
detected by this method, because some of them do not lead to protein stabilization. It is 
possible that some TP53 mutations result in negative immunostaining or wild type TP53 
gene may be associated with p53 protein overexpression (Strano et al, 2007). Consequently, 
direct sequencing of the TP53 gene is probably the most important component for any TP53 
evaluation at present. 
4.1.3 Clinical evaluation of TP53 status 
When the mutational analysis of TP53 and the clinical outcome in patients with HNSCC as a 
whole are correlated, studies have reported contradictory results even when using the same 
molecular techniques.  The correlation between p53 expression and clinical outcome in 
patients with HNSCC, however, has been questioned (Thomas et al, 2005) (Table 3). A 
number of studies have shown that TP53 gene mutations are associated with an increased 
risk for locoregional recurrence and poor outcome (Thomas et al, 2005).  Furthermore, a 
significant correlation between p53 expression and clinical outcome appears to be strongest 
in the subgroup of patients with laryngeal SCC (Narayana et al, 1998; Nylander et al, 2000). 
Although there are many studies correlating mutations or overexpression of p53 with poor 
outcomes, others have shown that TP53 mutations or overexpression do not independently 
predict clinical outcomes in patients with HNSCC (Thomas et al, 2005). Possible 
explanations for incongruity between these studies may be due to a failure of 
immunohistochemical techniques to detect actual TP53 mutations, differences between 
races, variation in tissue handling and analysis techniques and variation in the definition of 
overexpression (Strano et al, 2007(b); Thomas et al, 2005). In addition, differences observed 
in the impact of TP53 alterations on prognosis may be due to different treatment methods. 
In fact, a predictive role of TP53 mutations on treatment responses, in particular in 
radiotherapy and chemotherapy, was demonstrated (Blons et al, 2003). Furthermore, in the 
TP53 mutations located in the DNA binding domain, the chance of a major response to 
chemotherapy treatments were inferior. Finally, the accumulation of mutant p53 protein 
leads to the production of anti-p53 antibodies. Their presence is significantly correlated with 
increased risks of recurrence and death (Blons et al, 2003). 
4.1.4 Therapy by reactivation or elimination of mutant p53 protein 
HNSCC has been one of the first tumour localities to benefit from gene transfer therapy. The 
transfection of wild type TP53 into cell lines induced growth arrest and reduced 
tumourigenicity in nude mice. This suggested that restoring p53 function in HNSCC could 
inhibit cell growth (Strano et al, 2007(b)). Therapeutic strategies based on p53 tumour 
suppressor function were initiated. One of these approaches is based on the functional 
correction of mutant p53 protein using short synthetic peptides derived from the C-terminus 
of wt-p53. In particular, these peptides can increase the DNA binding ability of wt-p53 and 
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restore the transcriptional activity of some gain of function mutants. This application is 
severely restricted by the complexity of the synthesis, stability limitations, restricted uptake 
and intracellular processing. Stabilizing the native form of p53 protein (correctly folded) by 
shifting the equilibrium from its denatured form was another idea. As a consequence of the 
re-acquired native folding, some p53 mutants are able to activate wt-p53 target genes and 
promote apoptosis (Strano et al, 2007(b)). Finally, the last therapeutic strategy is based on 
the elimination of mutant p53. The efficient replication of adenovirus requires the 
neutralization of p53 function through E1B viral protein. ONYX-015 is an engineered 
adenovirus that does not express E1B protein and consequently is unable to inactivate p53. 
The infection of tumour cells carrying TP53 mutations with ONYX-15 provokes apoptosis. 
Clinical trials are underway in HNSCC patients. While the treatment with ONYX-15 alone 
gave only marginal effects, its combination with cisplatin and 5-fluorouracil had a more 
profound impact on the response of patients (Strano et al, 2007(b)); Perrone et al, 2010). 
4.1.5 Oncogenic properties: Gain of function of mutant p53 
Mutant p53 proteins are unable to transcriptionally regulate wt-p53 target genes and to 
exert its antitumoral effects such as apoptosis, growth arrest, differentiation and senescence. 
On the other hand, countless evidence has demonstrated that at least certain mutant forms 
of the p53 protein may possess gain of function activity, thereby positively contributing to 
the development, maintenance and spreading of many types of tumours, including HNSCC 
(Gasco & Crook, 2003; Strano et al, 2007(a)). A great amount of in vitro and in vivo evidence 
have firmly established an oncogenic role of certain missense TP53 mutations (such as 
p53R175H), located especially in the DNA binding domain (Strano et al, 2007). The resulting 
protein is a full-length protein, with a single aminoacid change that is sufficient to make 
them unable to recognize the wt-TP53-DNA consensus on target gene promoters. In 
addition, the half-life of mutant p53 protein is extremely prolonged compared to that of w.t.-
p53. It has been hypothesized that mutant p53 proteins could serve as oncogenic 
transcription factors. By genome-wide expression profile techniques it has been shown that 
p53 mutant proteins can modulate sets of genes involved in oncogenic activities (Strano et 
al, 2007). Furthermore, the semiquantitative SnaPshot analysis in HNSCC TP53 mutant 
patients shows a higher expression of missense mutant allele compared to w.t. These data 
demonstrate that TP53 missense and nonsense mutations have a dissimilar allelic expression 
imbalance (AEI) behavior in HNSCC, mostly likely independent from the LOH TP53 status. 
The positive AEI in favour of TP53 missense mutations could be due to the inactivation of 
w.t. allele, as well as to the higher expression or mRNA stability of mutant allele (Ganci et 
al, 2011). Comparatively, the low expression of the nonsense mutations compared to the w.t. 
allele in HNSCC tissue may be due to the nonsense mediated decay (MND) surveillance 
pathway, which ensures the rapid degradation of the mRNAs containing premature 
translation termination codons (Behm-Ansmant et al, 2007). 
4.1.6 p53 as a marker for the clonal heterogeneity identification of tumor cells 
The most striking features of HNSCC are its histopatological heterogeneity and the disparity 
between biological behavior, which is extremely variable, and morphological classification. 
It is well recognized that patients with similar stages of head and neck cancer may have a 
diverse clinical course and response to similar treatment (Kearsley et al, 1990). Considerable 
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intratumor heterogeneity for genetic alterations has been demonstrated, as shown in the 
genetic analysis by LOH and MSI on chromosomes 17p13 (p53) and 9p21 (RPS6) (Wang et 
al, 2006). They examined the differential genetic composition of the histological high-grade 
and low-grade areas showing an increase of aberration proportions for both loci in the 
poorly differentiated region of the tumour. Similar results were obtained by the 
immunohistochemistry (IHC) analysis of mutant p53 staining from hematoxylin and eosin 
HNSCC sections (Ganci et al, 2011; Wang et al, 2006; Boyle et al, 1993). A higher number of 
p53 positive cells were observed in poorly differentiated regions than in moderately or well 
differentiated ones (fig.2). Furthermore, data from cloning and sequencing p53 cDNA in 
tumours carrying double and triple p53 mutations showed that different p53 mutated alleles 
were present (Ganci et al, 2011). On the other hand, HNSCC tissues carrying double/triple 
p53 mutations on different alleles showed a positive, but not homogenous p53 staining, 
independently from the state of tumour cell differentiation, probably relying on the 
presence of clonal populations carrying different TP53 mutations in the same tumour (Ganci 
et al, 2011) (fig.2). The intratumour heterogeneity, which was also demonstrated for the 
methylation status (Varley et al, 2009), could be due to multiple different processes of 
carcinogenesis, where clonal populations arising within tumours may undergo separate 
individual genetic changes conferring different aggressiveness capacity. 
 
                                  (a)                                 (b) 
(a) p53 Y234C protein shows positive staining by IHC. A higher number of p53 positive cells was 
observed in poorly differentiated (red arrow) tissue areas than in moderately or well differentiated ones 
(black arrow). (b) The tissue carrying the two TP53 mutations C242Y and Del.T155-M169 (deletion of 
40bp) on separate alleles shows overexpression of p53 protein. A positive, but not homogeneous, p53 
staining was observed by IHC independently from the tumor cell differentiation state, probably relying 
on the presence of clonal populations carrying different TP53 mutations in this tumor. Red and black 
arrows indicate regions with positive and negative p53 staining, respectively, in a poorly differentiated 
tumor area.  
Fig. 2. p53 as a marker for the clonal heterogeneity in HNSCC 
4.1.7 HPV infection and correlation with p53 status 
Similar to tobacco and alcohol use, oral human papilloma virus (HPV) infection, plays a role 
in the pathogenesis of HNSCC. The transforming potential of high-risk, oncogenic types (as 
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HPV-16, 18), is largely a result of the function of two viral proteins, E6 and E7, which 
functionally inactivate two human tumour suppressor proteins, p53 and pRB, respectively. 
Expression of high-risk HPV E6 and E7 results in cellular proliferation, loss of cell cycle 
regulation, impaired cellular differentiation, increased frequency of spontaneous and 
mutagen-induced mutations and chromosomal instability (Chung & Gillison, 2009) (fig. 3). 
HPV was detected in about 20% of HNSCC cases especially in oropharynx and oral cancer 
(Leemans et al, 2011; Rosenquist et al, 2007). The possible involvement of TP53 status and 
HPV infection was suggested by several studies in which HPV DNA was detected and 
almost all positive cases were w.t. for TP53 (fig. 4) (Smith et al, 2010; Mitra et al, 2007). HPV 
positive cancer was also associated with a significantly better prognosis than HPV negative 
cases, which have a higher frequency of TP53 mutations. Altogether, these data support the 
evidence that HPV positive HNSCC is a distinct pathobiological and clinical disease 
component (Leemans et al, 2011).  
 
The human papillomavirus (HPV) genome contains various early and late open reading frames and 
encodes two viral oncoproteins: E6 and E7. The E6 protein binds p53 and targets the protein for 
degradation (by ubiquitination), whereas the E7 protein binds and inactivates the Rb pocket proteins. 
The molecular consequence of the expression of these viral oncoproteins is cell cycle entry and 
inhibition of p53-mediated apoptosis, which allows the virus to replicate E6AP=E6 adaptor protein. 
Fig. 3. HPV infection affects cell cycle.  
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                                    a)                                   b) 
a) In HPV + HNSCC the oncoprotein HPV E6 promotes p53 degradation. Consequently p53 protein 
expression is not detected in the tumor by IHC. p53 inactivation by HPV causes loss of its tumor 
suppressor function. 
b) In HPV- HNSCC, p53 tumor suppressor function is mainly inactivated by 17p13 deletion and/or 
TP53 mutations. A subset of TP53 mutations, mainly missense mutations, show not only loss of tumor 
suppressor properties, but also gain of oncogenic functions. These mutations are often associated with 
p53 protein overexpression by IHC. 
Fig. 4. Correlation of TP53 status and HPV infection in HNSCC 
4.1.8 P72R TP53 polymorphism  
A common polymorphism exists in exon 4 of the TP53 gene resulting in the expression of 
either arginine (R) or proline (P) at codon 72 (Matlashewski et al, 1987). This sites is within 
the apoptosis-signalling domain of the protein. The R form of w.t. p53 is more leading to the 
hypothesis that individuals homozygous for R in the germ-line are at higher risk of HPV 
associated cancers than carriers of other genotypes (Storey et al, 1998). Several studies have 
addressed this possibility in HNSCC, but none have identified an increased frequency of 
any codon 72 genotype. Despite the apparent absence in the association between codon 72 
genotype and risk of HNSCC, there is evidence demonstrating that the clinico-pathological 
characteristics of cancers may be affected by polymorphism (Gasco & Crook, 2003). Loss of 
the 72P allele has been reported in several studies. In a small series of HNSCC from 
northern Europe and Japan, there was a clear bias for TP53 mutants to target the 72R allele 
and for LOH to involve the 72P. 72R mutants more potently inhibit p73, a protein belonging 
to the p53 family, than equivalent 72P mutants. It is a persuasive possibility that preferential 
retention of 72R mutants in HNSCC is a reflection of this activity (Gasco & Crook, 2003). The 
study of the effect of this polymorphism on clinical outcomes of HNSCC will be of  
great interest. 
4.2 Other potential molecular prognostic markers  
EGFR is a transmembrane tyrosine kinase capable of promoting neoplastic  transformation. 
Binding to the extracellular domain of EGFR causes the activation of a number of 
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downstream effectors including the activation of tyrosine kinase and activation of 
intracellular Ras, Raf and mitogen-activated protein kinase cascades. They are involved in 
malignant transformation and tumour growth through the inhibition of apoptosis, cellular 
proliferation, promotion of angiogenesis and metastasis. The EGFR family includes EGFR, c-
erbB2, c-erbB3 and c-erbB4, which have the ability to form receptor heterodimers and 
crosstalk between them. Both EGF and the transforming growth factor (TGF)-alpha are 
ligands that bind to EGFR (Thomas et al, 2005; Kalyanrshna & Grandis, 2006). EGFR 
expression has been extensively studied in HNSCC and its overexpression reported in 34-
80% of HNSCC using IHC (Beckhardt et al, 1995; Grandis et al, 1993). However, EGFR 
expression may occur in two stages, the over-expression in normal and well-differentiated 
epithelia adjacent to the tumour and the upregulation from dysplasia to HNSCC that may 
result from gene amplification. This marker has been significantly associated with short 
disease-free survival, overall survival and poor prognosis in HNSCC patients (Table 3). Data 
showing an increased expression of EGFR in well and moderately differentiated tumour 
cells and in dysplastic tissue compared with poorly differentiated tissue, suggest that EGFR 
upregulation may be an early event during HNSCC carcinogenesis. Co-expression of Her2 
and Her3, which do not have intrinsic tyrosine kinase activity, is reported to increase 
transforming activity, and their expression has been strongly associated with shortened 
patient survival (Thomas et al, 2005). EGFR over-expression has been shown to be an 
independent prognostic factor for neck node relapse in primary specimens of patients with 
laryngeal cancer (Almadori et al, 1999). Increased tumour resistance to cytotoxic agents, 
including radiotherapy has been associated with EGFR over-expression in HNSCC, in 
addition to its association with more aggressive tumour behavior (Thomas et al, 2005). This 
suggests that the evaluation of EGFR status at the time of diagnosis may help identify 
subsets of patients, who are at increased risk of neck node metastasis, may have an 
unfavorable radiotherapy treatment outcome and may therefore benefit from more 
aggressive treatments. Several studies, however, have found no association between EGFR 
and clinical stage, including lymph node status, extracapsular invasion, recurrence or 
survival in specimens from HNSCC patients using IHC, Western or Southern blot 
techniques (Thomas et al, 2005; Glazer et al, 2009). Qualitative and quantitative  
differences in techniques for determining EGFR positivity and cut-off levels may be 
significant factors contributing to the disagreement between studies. Nonetheless, the 
prognostic significance of EGFR in HNSCC in a great number of studies has compelled the 
development of therapeutic strategies to block EGFR signal transduction system and, 
theoretically, downregulate tumour growth. The use of antibodies against EGFR or 
inhibitors of tyrosine kinase in combination with chemotherapy or radiotherapy are 
underway in various cancer systems including HNSCC (Glazer et al, 2009; Chang & 
Califano, 2008; Uribe & Gonzalez; 2011). 
Cyclin D1 (CCND1) is a proto-oncogene located on chromosome 11q13 involved in the 
regulation of cell cycle transitions. Overexpression of CCND1 has been shown to shorten the 
G1 phase of the cell cycle (Motokura & Arnold, 1993). Abnormalities in cyclin D1 may result 
from genomic inversion, transloction or gene amplification (Leemans et al, 2011). However, 
overexpression may occur in the absence of gene amplification through a not well-
characterized mechanism, which may precede gene amplification.  Early dysregulation of 
CCND1 expression may occur during head and neck tumourigenesis (Izzo et al, 1998). 
Amplification and/or over-expression of CCND1 have been demonstrated in 17–79% of 
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tumour specimens from HNSCC patients by IHC, FISH or RT-PCR. CCND1 shows a higher 
incidence in hypopharyngeal and laryngeal carcinomas between 41% and 64% and a rare 
incidence (8%) in tonsillar carcinomas. Gene amplification is the most commonly reported 
alteration of CCND1. Its amplification and/or overexpression have been shown to correlate 
significantly with tumour extension, regional lymph node metastases and advanced clinical 
stage of HNSCC (Thomas et al, 2005; Quon et al, 2001). In addition, many studies show 
convincing data of CCND1 aberration as a prognostic marker for disease-free survival and 
overall survival in patients with this disease (Table 3). In particular, its overexpression was 
associated with an adverse disease free survival, independent of T and N (Quon et al, 2001). 
In contrast, other data found no significant associations between levels of CCND1 and 
survival of patients with HNSCC (Vielba et al, 2003). As most of the studies on CCND1 
utilize IHC in paraffin-embedded tissue from patients with HNSCC to examine the 
expression of CCND1, reasons for the differences between these studies are not clearly 
evident. However, differences in parameters for grading immunohistochemical staining 
may account for some of these discrepancies.  In addition, the retrospective selection of 
patients for analysis may influence the outcome of these studies. Several studies 
documented the independent value of cyclin D1 overexpression, particularly when 
combined with the loss p16 expression. In fact, significant correlation with poor clinical 
outcome measures of recurrence, metastasis and survival was seen when both of these 
genetic aberrations occur together than either alone (Thomas et al, 2005).  
p16 protein, which is encoded by the CDKN2A  tumour suppressor gene on chromosome 
9p21, inactivates the function of cdk4-cdk6-cyclin D complexes (Leemans et al, 2011). Loss of 
heterozygosity of the short arm of chromosome 9 (9p21-22) has been reported with high 
frequency in dysplasia, carcinoma in situ and HNSCC, suggesting that this  
genetic alteration may be involved in the early developmental stages of this disease 
(Thomas et al, 2005). Loss of p16 expression, mostly homozygous deletions and 
methylations is present in 52–82% of tumours from HNSCC patients using various detection 
techniques such as IHC and RT-PCR (Thomas et al, 2005). Using fluorescence in situ 
hybridization (FISH), p16 deletion was significantly associated with development of distant 
metastases (Table 3) (Namazie et al, 2002). In addition, using PCR-based techniques, a 
prospective study of locally advanced laryngeal SCC identified p16 mutation as an 
independent predictive factor for disease relapse and death (Bazan et al, 2002). In addition, 
downregulation of p16 was associated with a more locally advanced tumour (Thomas et al, 
2005). HPV infection has an important role in understanding p16 role as a prognostic marker 
in HNSCC. It is well established that in HNSCC detected with HPV oncoproteins, p16 
overexpression or TP53 wild type have a better prognosis (Leemans et al, 2011; Smith et al; 
2010). In particular, HPV infection has been demonstrated to play a role in the molecular 
pathways through its viral oncoproteins, E6 and E7 (Chung & Gillison, 2009). They increase 
degradation of p53 and interfere with pRB function leading to upregulation of p16 by loss of 
negative feedback control. It was shown that recurrence free-survival were highest in the 
HNSCC patients positive for HPV infection, having p53 wild type and overexpressing p16 
(Leemans et al, 2011). 
Cyclooxygenase (COX) is an enzyme that is responsible for the formation of prostanoids 
(prostaglandins, prostacyclins, and thromboxanes) which are involved in the inflammatory 
response. Two isoforms of Cox, Cox-1 and Cox-2, have been described. Although Cox-1 is 
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constitutively expressed in various tissues, Cox-2 expression is undetectable in most tissues 
and may play an important role in carcinogenesis and in the pathophysiologic progression 
of HNSCC (Thomas et al, 2005; Lin et al, 2002). Overexpression of Cox-2 in premalignant 
lesions such as oral Leukoplakia and HNSCC by the techniques of quantitative RT-PCR, 
IHC or immunoblotting has detected (Thomas et al, 2005). Cox-2 expression can be induced 
by various stimuli including a variety of cytokines, hormones and tumour promoters such 
as benzopyrene, a carcinogenic agent involved in head and neck tumorigenesis. Cox-2 
enzyme contributes to carcinogenesis by catalysing the synthesis of mutagens decreasing 
programmed cell death or apoptosis, increasing inflammation and immunosuppression, 
increasing new blood vessel formation or angiogenesis and increasing potential for invasion 
and metastasis (Eling et al, 1990; Tsujii & DuBois, 1995; Gallo et al, 2001; Thomas et al, 2005). 
Cytoplasmic expression of Cox-2 has been demonstrated in 70–88% of specimens from 
HNSCC patients with HNSCC using IHC and in 87% of tumour specimens using RT-PCR. 
In addition, expression of Cox-2 is significantly higher in tumour specimens with confirmed 
cervical lymph node metastasis and in advanced and poorly differentiated tumours of 
HNSCC (Table 3) (Thomas et al, 2005). Expression of Cox-2 was also found to be a 
significant prognostic marker in patients with premalignant lesions (Sudbo et al, 2003), and 
is an independent predictor of disease-free survival (Itoh et al, 2003), but not overall survival 
in patients with OSCC. Interestingly, one study suggested that patients with Cox-2-negative 
tumours, measured using IHC and Western blot analysis, had a worse clinical outcome as 
compared to patients bearing a Cox-2-positive laryngeal SCC (Ranelletti et al, 2001). 
Furthermore, COX-2 expression was noted in all laryngeal cancer specimens using IHC, and 
again, a lack of correlation between Cox-2 expression and clinicopathologic variables such 
as primary tumour size, stage, survival, recurrence or metastases was reported for these 
patients (Thomas et al, 2005). Despite these results, numerous studies in various cancer 
systems suggest that Cox-2 activity is important in the progression of epithelial cancers. 
Vascular endothelial growth factor-A (VEGF-A) is one of the key angiogenic factors 
promoting neovascularization in cancer, including HNSCC (Lim, 2005). It induces 
proliferation, migration and survival of endothelial cells during tumour growth by binding 
to specific tyrosine receptor kinases. Six members of the VEGF family have been identified: 
VEGF-A/ vascularpermeability factor (four isoforms), VEGF-B/VEGF-related factor, VEGF-
C/VEGF-related protein, VEGF-D/c-fos-induced growth factor, VEGF-E and placenta 
growth factor, and abnormal regulation of angiogenic factors have been implicated in the 
pathogenesis of cancer. In particular, VEGF-A has been described as an important 
prognostic factor in many types of human cancer (Thomas et al, 2005). Several retrospective 
studies in HNSCC have demonstrated that VEGF-A (Teknos et al, 2002) and VEGF-C 
(Tanigaki et al, 2004) expression is associated with clinicopathological factors and/or poor 
patient’s outcome, suggesting that they could serve as a prognostic marker also in HNSCC 
(Table 3). Many studies have shown that VEGF-A, as well as VEGF-C, are upregulated in 
head and neck cancers, thus stimulating proliferation of vascular and lymphatic endothelial 
cells, and increasing vessel permeability (Thomas et al, 2005). The enhanced angiogenic 
activity could sustain growth of the primary tumour, potentiate dissemination and also 
support the establishment of micrometastases (Onesto et al, 2006). This is consistent with the 
strong association observed in different studies between VEGF-A expression and distant 
recurrence. It was also demonstrated that VEGF-A protein levels are closely associated to 
overall survival (Onesto et al, 2006). Subsequently, multivariate analysis showed that VEGF-
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A expression is an independent prognostic factor for overall survival. However, the status of 
VEGF-A remains unclear since other HNSCC retrospective studies have shown no 
correlation between VEGF-A expression and prognosis (Onesto et al, 2006; Thomas et al, 
2005). These conflicting results may be due partly to the method of detection of VEGF-A 
expression (i.e.IHC), used in most of the previous reports, and which is a semiquantitative 
method. A contributing factor for these discrepant studies may be related to the lack of a 
direct technique to measure angiogenic activity in tissue specimens. By using a 
semiquantitative method (i.e. IHC) as well as a quantitative method (i.e. ELISA), it is shown 
that VEGF-A expression is significantly associated with the tumour differentiation stage, 
poorly differentiated tumours expressing higher VEGF-A levels than highly differentiated 
tumours in head and neck carcinomas (Onesto et al, 2006; Thomas et al, 2005). In conclusion, 
markers related to tumour neovascularization can also predict the outcome in head and 
neck cancer patients. 
Transforming growth factor alpha (TGF-α) is upregulated in some human cancers, 
including HNSCC. It is produced in macrophages, brain cells, and keratinocytes, and 
induces epithelial development. It competes with EGF for EGFR binding, which also results 
in receptor activation and cellular proliferation. By using IHC analysis, it was demonstrated 
that TGF alfa is elevated in HNSCC and in the adjacent histologically normal mucosa 
compared to normal control mucosa. The prognostic significance of TGF alfa has not been as 
widely studied as that of EGFR, but there is suggestive evidence that its overexpression may 
predict an increased risk of recurrence and adverse survival in HNSCC patients (Table 3) 
(Quon et al, 2001; Leemans et al, 2011).  
MMPs. The capacity of head and neck cancer to invade adjacent tissues and develop 
locoregional metastasis often presents serious problems in clinical management. Cancer cell 
invasion, metastasis and angiogenesis is a complex, multistep process, involving the 
cooperation of multiple proteolytic enzymes that are secreted by tumour and/or host cells 
and whose substrates include extracellular matrix (ECM) components. The matrix 
metalloproteinases (MMPs) are a family of zinc- and calcium-dependent endopeptidases 
that can collectively degrade virtually all protein components of the ECM. Degradation of 
collagen matrix is important for HNSCC to invade surrounding tissues and metastasize to 
regional and distant organs (Thomas et al, 2005; Lim, 2005) MMP-2 and MMP-9, believed to 
play a major role in tumour invasion and metastasis in HNSCC, degrade type IV collagen, 
the main component of basement membrane (Stetler-Stevenson et al, 1993). MMPs can be 
inactivated by naturally occurring tissue inhibitors of MMPs (TIMPs). Expression of TIMPs 
has also been associated with poor prognosis in HNSCC patients (Thomas et al, 2005). 
Various MMPs are over-expressed in HNSCC including MMP-2, MMP-8, MMP-9 and 
MMP-13 (Thomas et al, 2005; Ha et al, 2009). These have been detected mainly with the 
immunohistochemical analysis of paraffin-embedded primary tumours.  MMP-9 is over-
expressed in 60-92% of HNSCC and was positively correlated to the over-expression of 
proto-oncogene eIF4E (Nathan et al, 2002). Correlation of expression of MMP-9 with 
traditional clinicopathogic variables or with measures of clinical outcome in patients with 
HNSCC remains controversial (Table 3). Over-expression of MMP-9 has been significantly 
correlated with histologic grade, advanced tumour stage and lymph node metastases of 
HNSCC at diagnosis. Alternatively, the correlation between the expression of MMP-9 and 
traditional clinical prognostic factors such as tumour and lymph node stages has not been 
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demonstrated in HNSCC patients (Thomas et al, 2005). Differences in the clinical stages of 
patients at presentations and differences in treatment modalities have been proposed as 
possible factors contributing to the discrepancies between these studies. The MMP-2 
expression in HNSCC at the invasive front in advanced HNSCC was significantly correlated 
with overall survival, early recurrence in lymph node negative patients and lymph node 
metastasis (Table 3). In addition, studies from serum samples of HNSCC patients showed 
that high serum levels of soluble E-cadherine, MMP-9, active MMP-13, and presence of 
antibody anti-p53 were found to be significantly associated with poor survival and the 
presence of lymph node metastasis (Thomas et al, 2005). This demonstrates that the 
combined determination and evaluation of tumour markers may improve the diagnosis of 
lymph node metastasis in HNSCC. Finally, a recent study from a genome-wide 
transcriptional analysis of 25 HNSCC cell lines, having a different intrinsic cisplatin 
sensitivity, showed the possible use of MMP-7 and MMP-13, as novel predictive biomarkers 
for cisplatin resistance (Ansell et al, 2009). 
FHIT, which is located at chromosome 3p14.2, is a tumour suppressor gene that is 
frequently deleted in human cancers, including HNSCC.  Loss of Fhit protein expression has 
also been reported in some precancerous lesions of the oral cavity and esophagus (Tai et al, 
2004).  It has been found to be associated with exposure to environmental carcinogens, such 
as smoking and alcohol consumption. The loss or alterations of normal FHIT function in the 
context of cell growth or tumour suppression is still not known.  The role of Fhit as a 
prognostic marker in patients with HNSCC has not yet been clearly ascertained (Table 3). 
Reduction or loss of Fhit expression can be found in 53–68% of tumour samples from 
patients with HNSCC (Thomas et al, 2005). Data obtained by using IHC, Western blot and 
RT-PCR methods, show that a  low FHIT expression correlated with high expression of Ki-
67, suggest that FHIT-altered tumour cells may have high proliferation potential (Mineta et 
al, 2003). However, only a few studies have found a significant correlation between Fhit 
expression and prognosis of patients with HNSCC. Patients whose tumours showed low or 
no expression of Fhit had significantly shorter disease-free survival (Lee et al, 2001; Tai et al, 
2004). Interestingly, it has been shown that no reduction in Fhit expression by IHC predicted 
a significantly poorer outcome in patients with advanced oropharyngeal cancer (Otero-
Garcia et al, 2004). In this study, tumours from all patients that subsequently developed 
distant metastases showed no reduction of expression of Fhit. The authors did not provide a 
rationale for the discrepancy between their and other studies. In other studies, authors 
showed that loss of Fhit expression by IHC predicted significantly poorer overall survival 
and an increased rate of distant metastases in patients with HNSCC (Tai et al, 2004). The 
results of these studies suggest that Fhit expression, as a potential new marker in HNSCC, is 
still in question. Further studies to elucidate the potential role of this gene in HNSCC 
carcinogenesis are needed. 
Several other molecular factors may provide potential prognostic information for HNSCC 
patients. PTEN (Table 3), Ki67 and Bcl-2 are three of them. Ki67 is a marker  
reflecting cellular proliferation. Bcl-2 plays an important role in regulating apoptosis. The 
data on the prognostic role for Bcl-2 in HNSCC remain contradictory. Existing data show an 
association of Bcl-2 overexpression with recurrence and poor survival. On the other hand, 
there are also studies in which no correlations with clinical outcomes are reported (Ha et al, 
2009; Quon et al, 2001). 
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5. Molecular study of HNSCC 
HNSCC is a heterogeneous disease with complex molecular abnormalities. By using high 
throughput approaches generating gene expression and, more recently, microRNAs 
expression profiling, researchers may obtain a molecular classification and characterization 
of HNSCC, also in association with clinical parameters. 
5.1 Gene expression 
Gene expression signatures constitute an additional biological approach used to: identify 
screening and diagnostic molecular markers, improve tumour staging (cervical lymph node 
and distant metastasis prediction), differentiate lung metastasis of HNSCC from primary 
lung squamous cell carcinomas, predict tumour response to therapy, and provide outcome 
predictors (Lallemant et al, 2010). Two technologies are currently used: DNA microarrays, 
which extensively measures the expression of thousands of genes, and qRT-PCR, which 
provides a more accurate quantification of the expression of more limited number of 
transcripts. From a clinical point of view, gene expression profiling should provide more 
accurate information about the cancer consequently leading to a more personalized and 
improved treatment strategy (Choi & Chen, 2005). To date, more than 60 gene expression 
profiling studies from human clinical samples of HNSCC have been published, with 
variable objectives, methods and results. The most significant source of heterogeneity 
among DNA microarray profiling studies comes from the various methods of data 
generation and analysis. All microarray data analyses consist of two basic steps: 1) 
establishing a normalized hybridization signal for each transcript and 2) the subsequent 
statistical determination of the signal variations. Perhaps, the largest drawback of 
microarray-based examinations of HNSCC is the lack of a well-defined standard for their 
use, interpretation and validation. Variability in tissue procurement, tumour cell isolation, 
RNA extraction, choice of array platform can also explain the differences among several 
HNSCC gene expression studied. For instance, some authors included samples from 
different HNSCC locations, others focused on a specific site; some analyzed microdissected 
tumour epitheliums, others including the surrounding stroma (Choi & Chen, 2005). 
Furthermore, most studies relied on a very limited number of samples. Consequently, it is 
important to set a threshold percentage value of tumour cells content and the contribution 
of stromal cell contamination to genetic expression profiles. Another consideration in 
microarray experimental planning is choosing appropriate controls. It is possible to use 
matched or unmatched normal tissue samples as a control, in which matched tissue is taken 
from the same patient from whom the tumour sample was obtained, while unmatched 
sample is obtained from subjects without cancer. However, from the pooled gene expression 
data, it was possible to identify a group of genes reported by multiple studies to be 
significantly up-regulated and down-regulated in HNSCC (Choi & Chen, 2005; Lallemant et 
al, 2010). These genes were used to encode cytoskeletal and extracellular matrix proteins, 
inflammatory mediators, proteins involved in epidermal differentiation and cell adhesion 
molecules (Choi & Chen, 2005). Data suggested a global downregulation of genes that 
encode ribosomal proteins and enzymes in the cholesterol biosynthesis pathway, and an 
upregulation of genes that encode matrix metalloproteinases and genes involved in the 
inflammatory response (Choi & Chen, 2005). 
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5.1.1 Identification of HNSCC in body fluids: Blood and saliva 
During carcinogenesis, some cancer cells may migrate into the blood stream or be 
eliminated into natural cavities like the bladder, mouth and intestines. Recovering 
transcriptional biomarkers representing genetic cancer alterations in the serum, plasma, 
urine, semen or saliva of patients, have already proven to be feasible and potentially useful, 
even if to date there are a few and preliminary results (Sidransky et al, 1997; Lallelmant et al, 
2010). In a study, researchers compared a gene expression profile in the blood serum of 
HNSCC patients and control cases, aiming to identify a signature of 5 overexpressed genes 
and demonstrate the utility of serum in the HNSCC diagnosis. It is important to note that 
diagnostic biomarker detection in saliva of HNSCC patients is a promising field of research. 
To date, most studies have focused on DNA alterations (mutations or methylation) and only 
recently on mRNA detection. Among the genes correlated with the HNSCC diagnosis 
identified from the saliva, there are IL1beta, OAZ1, SAT, IL8, SAT and H3F3A (Li et al, 2006; 
Lallelmant et al, 2010).  
5.1.2 Gene expression profile and local metastasis prediction 
Metastatic spread is an extremely bad prognostic factor. It is responsible for the cause of 
death in 90% of all cancer patients (Mehlen & Puisieux, 2006). When cervical lymph node 
metastases are identified, more aggressive treatments are proposed either by surgery or 
radiotherapy. In presence of distant metastases, the disease is considered incurable and 
palliative treatments are indicated. Differences between metastatic and non-metastatic 
tumours may be detected. Data from fourteen studies demonstrated that specific differences 
in gene expression exist between N+ and N0 HNSCC (Lallemant et al, 2010).This difference 
can be used to predict the N status on initial diagnostic biopsy. On the contrary, a few 
studies have tried to find gene expression signatures that could predict the development of 
distant metastasis in HNSCC, but to date, poor results have been obtained (Choi & Chen, 
2005). Insufficient samples number may in part explain the failure of these studies. In this 
aspect HNSCC differs from other tumour types, such as breast or prostate cancer, where a 
metastasis signature was identified. Cervical lymph nodes seem to work as a filter for 
metastatic cells and could be a prerequisite in hematologic spread. The acquisition by the 
primary tumour of a metastatic genetic profile is not inevitably associated with the 
occurrence of a distant metastasis because this cervical immunological fence can prevent or 
delay their appearance (Braakhuis et al, 2006).  
One of the main difficulties during the diagnosis of HNSCC is detecting microscopic tumour 
clusters, known to be easily overlooked by conventional histopathological methods in 
lymph nodes and/or surgical margins (Lallemant et al, 2010). Micrometastases are 
responsible for cancer recurrence in the neck of patients classified as N0 and, who 
consequently did not receive a prophylactic treatment either by neck dissection or 
radiotherapy. Additional biomarkers may be of help to improve stratifying patients selected 
for sentinel node biopsy. As suggested by preliminary results, gene expression signatures 
may greatly facilitate the identification of micrometastases in N0 patients. In the same way, 
the development of high frequency recurrence may be due to the presence of microscopic 
cancer cells cluster in the resection margins disregarded by conventional microscopy 
(Lallemant et al, 2010). Among the molecular markers with proven predictive value for 
lymphatic disease are E-cadherin, podoplanin, p16, bmi-1 and LOX (Huber et al, 2011; 
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Lallemant et al, 2010). Until now, the published predictive factors for metastatic disease in 
early HNSCC are histomorphological parameters, like mode of invasion, depth of tumour 
infiltrations, grade of differentiation, lymphatic invasion and intratumoral lymphatic 
density (Huber et al, 2011). The combination of these identified molecular markers and the 
histopatological features could allow individual risk stratification with possible impact on 
treatment strategy.  
5.1.3 Gene expression to distinguish HNSCC lung metastasis 
In many cases, the most common site of a HNSCC distant metastasis is the lung tissue 
(Ferlito et al, 2001). Knowledge of whether this tumour is a lung primary cancer or an 
HNSCC metastasis is crucial in the patient’s decision making process in choosing 
treatment. Unfortunately, in the presence of a single pulmonary nodule of squamous cell 
origin, the distinction between the primary lung tumour and HNSCC metastasis is 
impossible to discern (Lallemant et al, 2010). To date, only two studies have tried to 
address this issue by using gene expression approach. A signature of 10 genes correctly 
predicted and identified the origin of the tumour, thus suggesting the likelihood in 
identifying the origin of histologically similar malignant lesions based on expression 
profiling (Vachani et al, 2007).   
5.1.4 Correlation between gene expression profiling and clinical outcomes 
Gene expression profiling in relation to outcome prediction has been investigated to help 
clinicians to better stratify patients according to tumour aggressiveness, define prognosis, 
and subsequently modulate treatment intensity. The first study that reported the possible 
use of gene expression profiling for outcome prediction identified a 375 gene signature that 
divides the 17 patients of their cohort into two groups with slightly different survivals 
(Belbin et al, 2002). Data from different studies show a set of genes which identify HNSCC 
patients with high and low risk of recurrence and survival (Lallemant et al, 2010). For 
instance, it seems that high level of osteonectin may be a powerful, independent predictor 
for short-disease free survival interval and poor overall survival. A few studies also 
combined DNA microarray and CGH data to correlate the gene expression changes with 
chromosomal dosage and structure alterations (Lallemant et al, 2010). To date, the ability of 
gene expression profiling to provide effective outcome predictor remains questionable and 
extremely challenging.  
In HNSCC, choosing the most efficient treatment for each patient is based on a TNM 
evaluation. However, a certain percentage of patients do not respond to treatment. Thus, 
the differences in gene expression profiles between responders and non responders may 
be identified. To date, only few studies have addressed this specific issue in relation to 
HNSCC (Lallemant et al, 2010). Among the identified potentially predictive genes for 
therapy response there are MDM2, erb2, H-ras, VCAM-1 (Ganly et al, 2007). However, 
although these studies provide support for the use of gene expression in predicting 
treatment response, their results are disappointing. Another confounding factor could be 
the combination of treatments used, consisting of two distinct biological mechanisms of 
action. Ongoing studies focusing on the development of a predictive response signature 
for radiotherapy alone or chemotherapy alone are more likely to be successful (Lallemant 
et al, 2010).  
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5.2 microRNAs expression profiling in HNSCC  
A class of small non-coding RNAs termed microRNAs (miRNAs) has recently been 
indicated as biomarker of some types of cancers (Nana-Sinkam & Croce, 2010). miRNAs are 
endogenous, small, non-coding RNAs of 17-25 nucleotides that are thought to regulate 
approximately 30% of human genes. miRNAs modulate gene expression at post-
transcriptional level, primarily through their partial complementarity with the coding 
region or 3’ untranslated region (UTR) of target mRNAs. This then leads to translational 
repression and/or degradation, therefore, the regulation of gene expression (Babu et al, 
2011). In rare cases, they may also promote translation (Lin et al, 2011).They are involved in 
essential biological activities such as cellular differentiation, proliferation, development, 
apoptosis and cell cycle regulation (Shiiba et al, 2010). The roles of miRNAs in cancer have 
been extensively investigated in the past few years. The relevance of miRNAs in cancer was 
suggested by the observed changes in expression patterns and recurrent amplification as 
well as deletion of miRNA genes in cancer (Shiiba et al, 2010; Chen et al, 2010). It has been 
shown that there are two types of cancer-related miRNAs: oncogenic or tumour suppressor 
miRNAs (Table 4) (Babu et al, 2011). miRNAs expression profiling has been performed by 
microarray analysis or qRT-PCR methods. Some microRNAs show consistently altered 
expressions by different studies. For example, the upregulated expression of miR-21, -31, -18 
and -221 has been reported in at least two different studies. Similarly, the expression of the 
miR-133a, -133b, -125a, -138, -139, -200c, -26b, -302b, -302c, -342, -371, and -373 is consistently 
reported to be down regulated in HNSCC (Shiiba et al, 2010). Except certain miRNAs, all 
published miRNAs profiling show little agreement. This may be due to various types of 
samples applied, to different qualities of material (FFPE or fresh tissue), different sampling 
locations/cell lines, methods for performing the assay and scope of the array. The sampling 
technique of the tumour tissue also influenced the proportion of tumor cells to non-tumor 
cells that may interfere with the sensitivity of real time PCR and microarray analysis. 
5.2.1 Functional analysis of miRNAs in HNSCC 
Potential tumour suppressor miRs: Several miRNAs are found to act as tumour 
suppressors in cancer and in HNSCC (Table 4). Reduced expression of almost all members 
of let-7 family has been observed in HNSCC by several studies (Babu et al, 2011). For 
example, it is shown that exogenous expression of let-7a promotes laryngeal cancer cells 
dysfunction by modulating proliferation, inhibiting metastasis and inducing apoptosis 
(Long et al, 2009). In addition, it was shown that let-7a affects RAS and c-Myc expression at 
protein level, thus leading to the modulation of apoptotic genes and oncogenes expression. 
Furthermore, reducing it into let-7d expression is associated with poor prognosis (Childs et 
al, 2009). Down regulation of miR-125a/b is also observed in HNSCC by independent 
studies. Functional data that involve introducing miR-125b into HNSCC cell lines result in a 
reduced cell proliferation. A possible molecular mechanism contributing to this effect might 
be ERBB2 targeting by miR-125a/b which has experimentally been demonstrated. In fact, a 
high level of ERBB2 expression was observed in HNSCC suggesting disruption of miRNA 
suppression of this gene (Babu et al, 2011). Down regulation of miR-133a/b was also 
reported. Knocking-in these miRs in HNSCC cells resulted in reduced cell proliferation or 
increased apoptosis (Wong et al, 2008 (a)). An increased levels of PKM2, the validated 
cellular target of miR-133a/b, has also been associated with cancer progression (Wong et al, 
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2008 (a)). Members of miR-200 family, such as miR-200a and miR-200b, are also down 
regulated in HNSCC. They target ZEB1/2, which act as transcriptional repressors of E-
cadherin. In this way, the down modulation with the miR-200 family, concomitantly to the 
overexpression of miR-155, may promote epithelial mesenchymal transition (EMT) (Babu et 
al, 2011; Chen et al, 2010). In addition, the role of miR-138 in metastasis has also been 
demonstrated; miR-138 modulates migration and invasion through targeting RhoC and 
ROCK2. The inhibition of miR-138 enhanced cell migration as well as invasion (Liu et al, 
2009). The expression of other miRs, such as miR-34c and miR-204, also correlates with 
invasion. Enhancing miR-204 expression directly leads to the reduction of proliferation, 
invasion and migration in HNSCC cell lines (Lee et al, 2010). Also microRNAs can be 
silenced by hypermethylation for the tumor suppressor genes. miR-137 and 193a are an 
example; they are downregulated in HNSCC (Kozaki et al, 2008). In addition, miR-137 
promoter hypermethylation is significantly associated with poorer average survival in a 
study of 67 HNSCC patients (Langevin et al, 2010).  
Potentional oncogenic miRs: Several miRNAs are found to act as oncogenic miRs in cancer 
and in HNSCC (Table 4). Overexpression of miR-106b-25 and 17-92 clusters was observed in 
cancer, including HNSCC, by independent studies (Babu et al, 2011; Shiiba et al, 2010). 
These clusters, targeting p21 mRNA, are linked with cell cycle dysfunction. In fact, knock-
down of both clusters in HNSCC cells results in a reduced proliferation rate. miRNA-
mediated deregulation of p21 is likely to play an important role in tobacco associated 
HNSCC carcinogenesis because it can negatively regulate p53-mediated DNA damage 
induced by carcinogens in tobacco smoke (Ivanovska et al, 2008). Another overexpressed 
putative oncogenic miR identified in HNSCC is miR-221, which is able to suppress the 
expression of cell cycle regulators p27 and p57 (Babu et al, 2011). Reduced expression of p27 
has been well reported in HNSCC. It has even been suggested that it may act as a biomarker 
for cancer progression (Queiroz et al, 2010). In addition, a role of the miR-106b-25 and 17-92 
clusters in controlling TGF-beta signaling pathway, which is deregulated in HNSCC,  is 
emerging (Leemans et al, 2011). Another common deregulation in miRs expression in 
HNSCC is the upregulation of miR-21. Transfection of this miR into HNSCC cell lines 
results in significant increased growth rate whereas inhibitor-driven knock-down of miR-21 
reduces cell proliferation. Furthermore, the inhibition of miR-21 was demonstrated to 
enhance cytocrome-c release, thereby promoting apoptosis (Babu et al, 2011). Finally, miR-
155 shows an increased level of expression in several cancers including HNSCC and its 
possible role in the carcinogenesis has been investigated (Babu et al, 2011). 
5.2.2 miRNAs as prognostic and diagnostic biomarkers associated with HNSCC: 
Correlation with clinical outcomes 
Several investigators have empathized the role of miRs as biomarkers for HNSCC (Table 5). 
In a recent study focusing on identifying miRNAs expression signatures in association with 
progressive leukoplakia using sequentially progressive samples, researches built a multi-
miR prognosis predictor (Cervigne et al, 2009; Babu et al, 2011). The predictors are 
composed of eight miRs. According to the proposed model of miR changes during the 
progression from leukoplakia to OSCC, the over-expression of a subset of miRs (miR-146b, 
miR-181b, miR-21, miR-345, mR-518b, miR-520g, miR-649 and miR-184) may be considered 
an early detectable event in oral tumour progression. This is because they were commonly 
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Oncogenic miRs References 
miR-106b-25 cluster - Ivanovoska et al, 2008; 
- Petrocca et al, 2008. 
miR-17-92 cluster - Petrocca et al, 2008 
miR-221 - Avissar et al, 2009 (a) 
miR-21 - Cervigne et al, 2009; 
- Kimura et al, 2010. 
miR-155 - Chang et al, 2008; 
- Hui et al, 2010; 
- Ramdas et al, 2009 . 
miR-31 - Liu et al, 2010 
miR-184 - Wong et al, 2008 (b); 
- Wong et al, 2009. 
Tumor suppressor 
miRs 
- References 
Let-7 family - Chang et al, 2008; 
- Hui et al, 2010; 
- Ramdas et al, 2009. 
miR-125a/b - Henson et al, 2009; 
- Park et al, 2009. 
miR-133a/b - Nohata et al, 2011 
miR-200 family - Park et al, 2009;  
miR-1 - Nohata et al, 2011 
Table 4. Altered microRNAs in HNSCC  
deregulated in progressive and malignant lesions and were unchanged or under-expressed 
in non-progressive lesions. In particular, miR-345, miR-21 and miR-181b are strongly 
associated with increased lesion severity during the transition from histologically pre-
malignant to malignant lesions. According to this model, the final stages of carcinogenesis 
may also involve changes in miR-196a and miR-206, which appear under-expressed in 
premalignant lesions and over-expressed in carcinomas. Interestingly, these miRs are 
predicted to target cancer-associated genes, e.g. TNFRSF10B, ACAT1, NFIB, CCL1, MSH2, 
ACYP1 and PCBP2 (miR-21); GRM1, MAP3K10, CCDC42, SNHG5 (miR-181b); TSPO, 
RFXDC1, ZNF133, MORN3 (miR-345) (Cervigne et al, 2009). However, the usefulness of 
miRs as prognostic factors has only begun to be explored. Data from the study of miR-205 
and Let-7d expression showed their association with locoregional occurrence and shorter 
survival (Childs et al, 2009). In addition, high expression of miR-205 can be used to detect 
positive lymph nodes, suggesting that this miR can be considered as a marker for metastatic 
HNSCC (Fletcher et al, 2008). Another similar study identified lower expression levels of 
miR-451 in HNSCC tumours as a strong predictor for recurrence (Hui et al, 2010). In a study 
that looked into identifying diagnostic miRs in the saliva, researchers reported significantly 
low levels of miR-125a and 200a in the saliva of OSCC patients compared to control subjects 
(Park et al, 2009). Another recent study reported high levels of miR-184 and miR-31 in 
plasma of OSCC (Wong et al, 2008 (b), 2009). The study also showed that miR-184 has 
antiapoptotic functions in HNSCC cell lines. In fact, the inhibition of its expression can 
reduce cell proliferation rates. Finally, an association with higher expression of miR-211 and 
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most advanced nodal metastases, vascular invasion and poor prognosis was demonstrated 
in HNSCC (Chang et al, 2008). 
 
Putative miR 
marker 
Properties as marker 
References 
mir-205  Prognostic value:  
 low expression is associated with loco-regional 
recurrence.   
 low expression of both miR-205 and let-7d is 
associated with poor survival 
 role of miR-205 down-regulation in epithelial-
mesenchymal transition of head and neck 
spindle cell carcinoma 
 miR-205 expression as a marker for detection 
of metastatic HNSCC 
- Childs et al, 2009; 
- Fletcher et al, 2008; 
- Kimura et al, 2010; 
- Zidar et al, 2011. 
Let-7d  Prognostic value:  
 down-regulation of let-7d in combination with 
miR-205 low expression is associated with 
poor survival 
 let-7d down-regulation promotes epithelial-
mesenchymal transition (EMT) and have a role 
in chemoresistance  
- Chang et al, 2011; 
- Childs et al, 2009. 
miR-211  Prognostic value:  
 high miR-211 expression is associated with a 
worse survival rate 
- Chang et al, 2008 
miR-31  Diagnostic marker:  
 detection of high miR-31 expression in plasma 
from oral cancer patients  
 miR-31 expression in plasma is remarkably 
reduced after tumor resection 
- Liu et al, 2010. 
miR-125a, 200a  Diagnostic marker:  
 detection of low miR-125a and miR-200a 
expression levels in the saliva of oral cavity 
cancers 
- Park et al, 2009. 
miR-184  Diagnostic marker:  
 detection of high mir-184 expression in plasma 
from oral cancer patients  
 miR-184 expression in plasma is remarkably 
reduced after tumor resection 
- Wang et al, 2009; 
- Wong et al, 2008 (b). 
miR-137  Prognostic marker:  
 miR-137 promoter methylation is associated 
with poor overall survival 
 miR-137 aberrant methylation is more evident 
in female gender 
- Langevin et al, 2010. 
miR-21  Prognostic value:  
 elevated miR-21 level was associated with 
worse survival outcome;  
 high expression of miR-21, in combination 
with miR-181b and miR-345 is associated with 
increased severity during progression 
- Avissar et al, 2009 (a); 
- Cervigne et al, 2009; 
- Fu et al, 2011; 
- Kimura et al, 2010. 
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Putative miR 
marker 
Properties as marker 
References 
miR-210  Marker of hypoxia and prognostic/predictive 
value:  demonstrated functional role in tumor 
survival under hypoxia 
- Gee et al, 2010 
miR-451  Strong predictor for relapse - Hui et al, 2010 
miR-221, miR-375  Diagnostic marker:  
 the expression ratio of miR-221 to miR-375 can 
distinguish the normal from tumor tissue 
- Avissar et al, 2009 (a) 
Table 5. microRNAs as putative biomarker in HNSCC 
5.2.3 Aetiologic agents and correlation with miRNAs expression 
Despite the relative recent discovery of microRNAs and their association with cancer, their 
correlation with the aetiologic agents of HNSCC is still ongoing. Until now, very few studies 
have focused on this area. Data from multivariate analyses showed that expression of miR-
375 increases with alcohol consumption. Though expression of miR-375 is lower in tumours 
compared to normal tissues, fine-tuning of miRNA expression can occur at the level of the 
tumour microenvironment and can vary according to exposures and locations of the tumour 
(Avissar et al, 2009 (b)). In this case, alcohol consumption may contribute to the altered 
expression of miR-375 within HNSCC tumours. The regulation of miRNAs is complex and 
perturbations of the normal homeostatic mechanisms responsible for overall epigenetic 
stability could play a crucial role in potentially carcinogenic gene expression. Higher 
expression of miR-375 was also found in pharyngeal and laryngeal tumours compared with 
tumours of the oral cavity (Avissar et al, 2009 (b)). This observation is consistent with 
several findings indicating that miRNA profiles are tumour and cell-type specific which can 
even accurately differentiate tumour subtypes. Furthermore, the productivity for differential 
expression of miR-375 in tissues might reflect etiology. The significant association observed 
between drinking and miR-375 expression coupled with its tendency for higher expression 
in pharyngeal and laryngeal tumours may suggest that the deregulation of miRNA by 
exposures occurs preferentially in certain tissues (Avissar et al, 2009 (b)). Until now, there is 
no apparent evidence on the correlation of microRNAs expression and tobacco smoke in 
HNSCC. It is known that alcohol and tobacco use are predisposing factors for developing 
HNSCC, but HPV is also known to be associated with HNSCC, especially in the oral cavity 
and oropharynx cancer. HPV positive tumours have distinct clinical, molecular and 
prognostic features (Leemans et al, 2011). Until now, there is only one study on the 
microRNAs expression profiling analysis and HPV status information of HNSCC patients 
(Lajer et al, 2011). Researchers using a microarray approach have observed that HPV clearly 
has an influence on the miRNAs expression profile on a set of 49 oral cavity and  
oropharynx patients compared to 39 control subjects. In particular, miR-145, 125a, and 126 
were reduced in HPV-positive HNSCC patients, while miR-363 expression was increased 
(Lajer et al, 2011). 
5.4.4 An overview on therapy in HNSCC: Curcumin as a potential therapeutic agent 
Standard treatment regimens for head and neck cancer depend on the stage of the disease. 
Early stage (stage I and II) tumours are treated primarily with surgery or radiotherapy, or 
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with a combination of both modalities resulting in similar local control and survival rates. 
Radiation may also be used postoperatively when surgical margins are close or positive, or 
if a perineural or lymphovascular invasion by tumour is found. More advanced (stage III 
and IV) cancers often require a combination of therapies consisting of surgery, radiation and 
chemotherapy which can result in a very high morbidity (Wilken et al, 2011). Platinum-
based agents form the backbone of the standard chemotherapeutic regimens for head and 
neck cancer. Cisplatin (cis diamminedichloroplatinum) is a widely used drug in the class of 
platinum-based chemotherapies. The efficacy of cisplatin in HNSCC is greatly increased 
when combined with other chemotherapeutic agents, such as taxanes (paclitaxel and 
docetaxel) and 5 fluorouracil (5-FU) (Adelstein et al, 2010). The potential adverse effects 
from the treatment for HNSCC are numerous (Wilken et al, 2011). Despite continuing 
research and advances in treatment, the clinical outcomes and overall survival rates for 
HNSCC have not improved significantly over the last several decades, with an overall 5-
year survival rate as low as 50%. As a result, there has been continuing investigation into 
potential alternative and less toxic therapies for head and neck cancer, aiming to achieve a 
more favorable clinical outcome while reducing treatment morbidity. The class of 
molecularly targeted therapies against the epidermal growth factor receptor (EGFR) is one 
such example, as EGFR is overexpressed in a number of head and neck cancers (Chang & 
Califano, 2008). Cetuximab is an anti-EGFR monoclonal antibody that was approved by the 
Food and Drug Administration in 2004 for the treatment of advanced colon cancer. In 2006, 
Cetuximab was approved for use in head and neck squamous cell carcinoma both in 
combination with radiotherapy for advanced HNSCC as well as single-agent therapy for 
platinum-refractory head and neck cancer. Several studies of cetuximab as an adjuvant 
agent with radiotherapy have demonstrated improved locoregional control and statistically 
significant increases in both progression-free and overall survival (Wilken et al, 2011). The 
addition of cetuximab to standard platinum-based chemotherapy in platinum-resistant 
recurrent or metastatic head and neck cancer has also been studied and demonstrated 
increased treatment efficacy and improved overall survival without a significant increase in 
toxicity (Wilken et al, 2011). Multiple molecular pathways such as NF-kB activation, EGFR 
and PI3K/AKT/mTOR signaling, STAT3 expression, the MAP kinase cascade and VEGF 
mediated angiogenesis have been shown to be deregulated in HNSCC and represent 
potential therapeutic targets (Choi & Chen, 2005; Leemans et al, 2011). While some 
promising results from such targeted therapies have been obtained, the complexity of 
interaction between these signaling pathways may contribute to the limited clinical response 
seen with the use of single-agent biologic therapies. Curcumin (diferuloylmethane) is a 
polyphenol derived from the Curcuma longa plant, commonly known as turmeric. Curcumin 
has been used extensively in Ayurvedic medicine for centuries, as it is nontoxic and has a 
variety of therapeutic properties including anti-oxidant, analgesic, anti-inflammatory and 
antiseptic activity (Wilken et al, 2011). More recently curcumin has been found to possess 
anti-cancer activities, mostly via its effect on a variety of biological pathways involved in 
mutagenesis, oncogene expression, cell cycle regulation, apoptosis, tumorigenesis and 
metastasis (Wilken et al, 2011). Curcumin has shown an anti-proliferative effect in multiple 
cancers, and is an inhibitor of the transcription factor NF-kB and downstream gene products 
(including c-myc, Bcl-2, COX-2, NOS, Cyclin D1, TNF-alpha, interleukins and MMP-9). In 
addition, curcumin affects a variety of growth factor receptors and cell adhesion molecules 
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involved in tumour growth, angiogenesis and metastasis (Wilken et al, 2011). As a natural 
product, curcumin is nontoxic. It has been studied in various in vitro and vivo models of 
head and neck squamous cell carcinoma with promising results. An overview of the current 
literature supports the spice’s utility in the treatment of head and neck cancer and its effect 
as a chemopreventive agent (Wilken et al, 2011). 
6. Conclusions 
To date, the study of molecular prognostic factors has been an evolution motivated by the 
desire to define more homogenous groups of patients for treatment selection. Expression of 
these markers in diagnostic biopsy specimens may be an additional tool for selecting 
patients that may benefit from more aggressive treatment. Although these findings may 
help focus on selecting markers for further analysis for their value in the understanding and 
management of HNSCC, there are limitations to utilizing the list of molecules such as genes,  
microRNAs or proteins. Disagreement between studies may be due to the variety of tumour 
sites, sensitivity of the techniques used, quality of the specimens studied and the arbitrary 
cut-off values setted. More importantly, a lack of uniformed curative protocols throughout 
these studies may significantly affect their outcome, as the choice of a treatment method 
may have a great impact on long term survival of HNSCC patients. Although the 
pathobiology of many of the biomarkers in HNSCC provides sufficient rationale for clinical 
trials on single potential therapeutic agents, a multimarker strategy in addition to clinical 
parameters, is likely to add importance to the risk management of patients with or at risk of 
HNSCC. In this regard, microarray technology may provide a means for screening HNSCC 
samples for the presence or absence of a large number of genes or other molecules 
simultaneously. Many studies strongly suggest that miRNAs play a crucial role and may be 
a biomarker in HNSCC. There is a great deal of evidence demonstrating how altered 
expression of selected miRNAs may contribute to the deregulation of biological pathways 
involved in cancer such as cell cycle, apoptosis, epithelial-mesenchimal transition. 
Elucidation of the molecular mechanisms for miRNAs that are strong predictors of clinical 
outcomes can lead to a more complete picture of the role of miRNAs in HNSCC. Thus, 
detailed investigations of miRNAs, concerning intercommunication among miRNAs and 
between miRNAs and mRNAs, altered protein expression induced by miRNAs and site 
specific miRNAs expression profiling, are required accordingly before future clinical trials 
of therapeutic applications. For instance, antisense targeting of miRNAs for therapeutic 
purposes is emerging as a promising approach. 
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